Subscribe to Dr. Mirkin's free FITNESS & HEALTH NEWSLETTER
POLYCYSTIC OVARY SYNDROME

If you are a woman who stores fat primarily in your belly, rather than your hips and can't lose weight, no matter how hard you try, you may have polycystic ovary syndrome and could be cured just by eating a diabetic diet and taking diabetic medicine. Women with this syndrome also have excess hair on their faces and bodies, lose hair on the top of their heads, often suffer from acne during their teen years, have a family history of diabetes, have irregular periods, often find it difficult to become pregnant, have high blood levels of triglycerides, have low blood levels of the good HDL cholesterol that prevents heart attacks and have multiple cysts on their ovaries.

All of these signs and symptoms are caused by inability to respond to insulin and having high blood insulin levels. A woman is born with around 4 million eggs in her ovaries. Each month, one egg ripens and drops from the ovary into the uterus. High blood insulin levels cause the ovaries to produce large amounts of a hormone called inhibin that prevents eggs from being released, so they stay on the varies to form cysts. These women are at high risk for heart attacks and uterine cancer, but both of these conditions can be prevented by diabetic diets and medicines.

If you think that you may have this condition, get a sonogram of your ovaries. Even if you don't have cysts, you could still have this condition. Then you should avoid all bakery products, pastas, sugar-added foods and drinks, and fruit juices and eat root vegetables and fruits only with meals. Also take the diabetic medication, Glucophage, before each meal.

1) Birdsall MA et al. Annals of Internal Medicine. January, 1997

2) NEJM 1996(August 29);335(9):617-623.

3) Finasteride (5 mg daily) or flutamide (259 mg twice daily) for 6 consecutive months. L Falsetti, D Defusco, G Eleftheriou, B Rosina. Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome. Gynecological Endocrinology 11: 4 (AUG 1997):251-257.

4) V Deleo, D Lanzetta, D Dantona, A Lamarca, G Morgante. Hormonal effects of flutamide in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 83: 1(JAN 1998):99-102.

5) O Acbay, S Gundogdu. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertility and Sterility 65: 5 (MAY 1996):946-949. Metformin does not decrease insulin resistance in PCOS. This finding suggests that the cellular mechanism of insulin resistance in PCOS is different from other common insulin-resistant states such as noninsulin-dependent diabetes mellitus and obesity.

6) E Velazquez, A Acosta, SG Mendoza. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstetrics and Gynecology 90: 3 (SEP 1997):392-395. Excellent editorial in The Lancet January 31, 1998 351:305-6. lots of references.

7a) LC Morinpapunen, RM Koivunen, A Ruokonen, HK Martikainen. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertility and Sterility 69: 4 (APR 1998):691-696. A Lidor, D Soriano, DS Seidman, J Dor, S Mashiach, J Rabinovici. Combined somatostatin analog and follicle-stimulating hormone for women with polycystic ovary syndrome resistant to conventional treatment. Gynecological Endocrinology 12: 2 (APR 1998):97-101. human urinary follicle-stimulating hormone (FSH) Somatostatin analog subcutaneously by means of an infusion pump, providing a total daily dose of 200 mu g starting from days 1-3 of the cycle.

7) Nestler JE et al. Effects of metformin on spontaneous and clomiphene-induced ovulation in polycystic ovary syndrome. NEJM 1998(June 25);338:1876-1880.

8) N Mauras, S Welch, A Rini, MW Haymond. Ovarian hyperandrogenism is associated with insulin resistance to both peripheral carbohydrate and whole-body protein metabolism in postpubertal young females: A metabolic study. Journal of Clinical Endocrinology and Metabolism 83: 6(JUN 1998):1900-1905.

9) JE Nestler, DJ Jakubowicz, A Falcon, VC Brik, N Quintero, F Medina. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. Journal of Clinical Endocrinology and Metabolism 83: 6(JUN 1998):2001-2005.

10) E Diamantikandarakis, A Mitrakou, S Raptis, G Tolis, AJ Duleba. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 83: 8(AUG 1998):2699-2705.

11) M Ciampelli, A Lanzone. Insulin and polycystic ovary syndrome: a new look at an old subject. Gynecological Endocrinology 12: 4 (AUG 1998):277-292.

12) RS Legro, AR Kunselman, WC Dodson, A Dunaif. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women. Journal of Clinical Endocrinology and Metabolism 84: 1(JAN 1999):165-169.

13) D Guzick. Polycystic ovary syndrome: Symptomatology, pathophysiology, and epidemiology. American Journal of Obstetrics and Gynecology. 179: 6 Suppl. S Part 2 (DEC 1998):S89-S93.

14) AE Taylor. Understanding the underlying metabolic abnormalities of polycystic ovary syndrome and their implications. American Journal of Obstetrics and Gynecology 179: 6 Suppl. S Part 2 (DEC 1998):S94-S100.

15) RS Legro. Polycystic ovary syndrome: Current and future treatment paradigms. American Journal of Obstetrics and Gynecology. 179: 6 Suppl. S Part 2 (DEC 1998):S101-S108.

16) SL Berga. The obstetrician-gynecologist's role in the practical management of polycystic ovary syndrome. American Journal of Obstetrics and Gynecology. 179: 6 Suppl. S Part 2 (DEC 1998):S109-S113.

17) DA Ehrmann, RB Barnes, RL Rosenfield, MK Cavaghan, J Imperial. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22: 1 (JAN 1999):141-146.

18) R Koivunen, T Laatikainen, C Tomas, I Huhtaniemi, J Tapanainen, H Martikainen. The prevalence of polycystic ovaries in healthy women. Acta Obstetricia Et Gynecologica Scandinavica 78: 2(FEB 1999):137-141. 14.2% (27/189).

19) PA Radon, MJ McMahon, WR Meyer.Impaired glucose tolerance in pregnant women with polycystic ovary syndrome.Obstetrics and Gynecology, 1999, Vol 94, Iss 2, pp 194-197.

20)V DeLeo, A laMarca, A Ditto, G Morgante, A Cianci.Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome.Fertility and Sterility, 1999, Vol 72, Iss 2, pp 282-285.

21) K Unluhizarci, F Kelestimur, F Bayram, Y Sahin, A Tutus.The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.Clinical Endocrinology, 1999, Vol 51, Iss 2, pp 231-236.

22)HJHMT vanDessel, PDK Lee, G Faessen, BCJM Fauser, LC Giudice.Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.Journal of Clinical Endocrinology and Metabolism, 1999, Vol 84, Iss 9, pp 3030-3035.

23) MFM Mitwally, NK Kuscu, TM Yalcinkaya.High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Human Reproduction, 1999, Vol 14, Iss 11, pp 2700-2703.

24) E Kousta, DM White, E Cela, MI McCarthy, S Franks.The prevalence of polycystic ovaries in women with infertility.Human Reproduction, 1999, Vol 14, Iss 11, pp 2720-2723.

25) RA Lobo, E Carmina. The importance of diagnosing the polycystic ovary syndrome. Annals of Internal Medicine, 2000, Vol 132, Iss 12, pp 989-993Address Lobo RA, Columbia Univ, Coll Phys & Surg, Dept Obstet & Gynecol, 630 W 168th St, New York,NY 10032 USA

26) Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. R Pasquali, A Gambineri, D Biscotti, V Vicennati, L Gagliardi, D Colitta, S Fiorini, GE Cognigni, M Filicori, AM MorselliLabate. Journal of Clinical Endocrinology and Metabolism, 2000, Vol 85, Iss 8, pp 2767-2774.

Reported 1/10/01; checked 9/4/05

May 16th, 2013
|   Share this Report!

About the Author: Gabe Mirkin, MD

Sports medicine doctor, fitness guru and long-time radio host Gabe Mirkin, M.D., brings you news and tips for your healthful lifestyle. A practicing physician for more than 50 years and a radio talk show host for 25 years, Dr. Mirkin is a graduate of Harvard University and Baylor University College of Medicine. He is board-certified in four specialties: Sports Medicine, Allergy and Immunology, Pediatrics and Pediatric Immunology. The Dr. Mirkin Show, his call-in show on fitness and health, was syndicated in more than 120 cities. Read More
Copyright 2016 Drmirkin | All Rights Reserved | Powered by Xindesigns